Long-Term Efficacy of Sandostatin®(SMS 201–995, Octreotide) in 178 Acromegalic Patients. Results from the International Multicentre Acromegaly Study Group
- 1 January 1988
- book chapter
- Published by Springer Nature
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Shrinking of a Growth Hormone-Producing Pituitary Tumor by Continuous Subcutaneous Infusion of the Somatostatin Analog SMS 201-995Journal of Clinical Endocrinology & Metabolism, 1987
- The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegalyActa Endocrinologica, 1987
- Medical Treatment of Acromegaly with SMS 201-995, a Somatostatin Analog: A Comparison with Bromocriptine*Journal of Clinical Endocrinology & Metabolism, 1987
- EFFECTIVE LONG-TERM TREATMENT OF ACROMEGALY WITH A LONG-ACTING SOMATOSTATIN ANALOGUE (SMS 201–995)Clinical Endocrinology, 1987
- A Comparison among the Growth Hormone-Lowering Effects in Acromegaly of the Somatostatin Analog SMS 201-995, Bromocriptine, and the Combination of Both DrugsJournal of Clinical Endocrinology & Metabolism, 1986
- Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1985
- LONG-ACTING AND SELECTIVE SUPPRESSION OF GROWTH HORMONE SECRETION BY SOMATOSTATIN ANALOGUE SMS 201-995 IN ACROMEGALYThe Lancet, 1984